Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: Early postmarketing evidence

Journal of Comparative Effectiveness Research

Volumn 4, Issue 2, 2015, Pages 89-99

  Morrato, Elaine H ^a,b   Parks, Joe ^c   Campagna, Elizabeth J ^b   Muser, Erik ^d   Thomas, Deborah S K ^e   Fang, Hai ^a   Doshi, Dilesh ^d  

^a Food Science and Human Nutrition   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MISSOURI INSTITUTE OF MENTAL HEALTH   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

atypical antipsychotics; comparative effectiveness; emergency department visits; hospitalization; Medicaid; paliperidone palmitate

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; PALIPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG UTILIZATION; EMERGENCY CARE; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; MENTAL DISEASE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SELECTION BIAS; SENSITIVITY ANALYSIS; SUBSTANCE ABUSE; UNITED STATES; ADOLESCENT; COMPARATIVE STUDY; EMERGENCY HEALTH SERVICE; EPIDEMIOLOGY; INJECTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS; LOGISTIC MODELS; MALE; MEDICAID; MIDDLE AGED; MISSOURI; PALIPERIDONE PALMITATE; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84926330137     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.14.50     Document Type: Article

References (32)

1. Clancy C, Collins FS. Patient-centered outcomes research institute: the intersection of science and health care. Sci. Transl. Med. 2(37), 37cm18 (2010).
2. Selby JV, Beal AC, Frank L. The patient-centered outcomes research institute (PCORI) national priorities for research and initial research agenda. JAMA 307(15), 1583-1584 (2012).
3. Sox HC, Greenfield S. Comparative effectiveness research: a report from the institute of medicine. Ann. Intern. Med. 151(3), 203-205 (2009).
4. Concannon TW, Meissner P, Grunbaum JA et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J. Gen. Intern. Med. 27(8), 985-991 (2012).
5. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst. Rev. 6, CD008296 (2012).
6. Zeber J, Miller A, Copeland L et al. Medication adherence, ethnicity, and the influence of multiple psychosocial and financial barriers. Adm. Policy Ment. Health 38(2), 86-95 (2011).
7. Achilla E, Mccrone P. The cost effectiveness of long-Acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl. Health Econ. Health Policy 11(2), 95-106 (2013).
8. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon. Outcomes Res. 3, 9-14 (2011).
9. Olivares JM, Peuskens J, Pecenak J et al. Clinical and resource-use outcomes of risperidone long-Acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr. Med. Res. Opin. 25(9), 2197-2206 (2009).
10. Peuskens J, Olivares JM, Pecenak J et al. Treatment retention with risperidone long-Acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr. Med. Res. Opin 26(3), 501-509 (2010).
11. Taylor D, Olofinjana O. Long-Acting paliperidone palmitate-interim results of an observational study of its effect on hospitalization. Int. Clin. Psychopharmacol. 29(4), 229-234 (2014).
12. Rosenheck RA, Krystal JH, Lew R et al. Long-Acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 364(9), 842-851 (2011).
13. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-Acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J. Clin. Epidemiol. 66(8 Suppl.), S37-S41 (2013).
14. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158(9), 915-920 (2003).
15. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project (Hcup). Clinical Classifications Software (CCS) for ICD-9-CM Fact Sheet (1 August 2007).
16. Morrato EH, Druss BG, Hartung DM et al. Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 67(1), 17-24 (2010).
17. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10(1), 3-12 (2007).
18. Nasrallah HA, Meyer JM, Goff DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86(1-3), 15-22 (2006).
19. Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med. Care 49(6), 599-604 (2011).
20. Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic. Dis. [serial online] (2006). www.cdc.gov/pcd/issues/2006/apr/05-0180.htm
21. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 316(7139), 1236-1238 (1998).
22. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide (AHRQ Publication No. 12(13)-EHC099). Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM (Eds). Agency for Healthcare Research and Quality, MD, USA (2013).
23. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399-424 (2011).
24. Parsons LS. Performing a 1:N case-control match on propensity score. SAS Users Group International Paper165-129 (2004).
25. Walker AM. Matching on provider is risky. J. Clin. Epidemiol. 66(8), S65-S68 (2013).
26. Soeteman DI, Perry CJ, Kim JJ. The use of comparative effectiveness research in mental healthcare policy and practice. J. Comp. Eff. Res. 3(1), 1-3 (2014).
27. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff. 29(10), 1818-1825 (2010).
28. Selby JV, Fleurence R, Lauer M, Schneeweiss S. Reviewing hypothetical migraine studies using funding criteria from The Patient-Centered Outcomes Research Institute. Health Aff. (Millwood) 31(10), 2193-2199 (2012).
29. The Henry J. Kaiser Family Foundation. State Medicaid Fact Sheets (10 June 2011). www.kff.org/statedata/
30. Gluck Me, Radomski L. The AcademyHealth Listening Project Report: Improving the Evidence Base for Medicare Policymaking. AcademyHealth, WA, USA (2014).
31. Goff DC. Maintenance treatment with long-Acting injectable antipsychotics: comparing old with new. JAMA 311(19), 1973-1974 (2014).
32. Armstrong PW, Furberg CD. Clinical trial data and safety monitoring boards. The search for a constitution. Circulation 91(3), 901-904 (1995).